Drugmakers told the FDA that inflexible post-approval change requirements are among the top regulatory barriers to the ...

Amgen's obesity drug MariTide shows promise in maintaining weight loss with less frequent dosing. In trials, it achieved up ...

An extension study of Amgen's experimental obesity drug MariTide found that it helped people maintain weight loss when given ...

Chief Executive Officer Bob Bradway told attendees at a J.P. Morgan-hosted event that the company views 2026 as a ...

AbbVie reached a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future ...

Amgen's study of the drug Maritide in people with Type 2 diabetes showed noteworthy reductions in HbA1c and weight. The ...

Pill versions of the successful GLP1 drugs from Novo Nordisk and Eli Lilly will likely be on the market in 2026’s first half.

Amgen's research chief said the company is very confident about its experimental obesity drug MariTide, as it prepares on ...

The atherosclerotic cardiovascular disease market in the 7MM is expected to show positive growth during the forecast period (2025–2034), mainly attributed to the launch of upcoming therapies such as ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO), has recommended approval ...

President Trump’s self-branded attempt to cut drug prices, TrumpRx, is set to launch within weeks, offering a novel pathway ...

SKYWAY (NCT07148414) is a Phase 2 basket trial of SPY072 (anti-TL1A) in patients with moderate to severely active RA, PsA, or axSpA. Enrollment is on track, and all indications are expected to readout ...